About invivyd inc - IVVD
Invivyd, Inc. engages in the discovery, development and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The firm develops antibodies that can neutralize SARS-CoV-2, SARS-CoV-1, and additional emergent coronaviruses. It offers ADG20, a monoclonal antibody, targeting the spike protein of SARS-CoV-2 and related coronaviruses. The company was founded by Tillman U. Gerngross, Ren Russo and Laura Walker on June 3, 2020 and is headquartered in New Haven, CT.
IVVD At a Glance
Invivyd, Inc.
205 Church Street
New Haven, Connecticut 06510
| Phone | 1-781-819-0080 | Revenue | 53.43M | |
| Industry | Biotechnology | Net Income | -52,489,000.00 | |
| Sector | Health Technology | 2025 Sales Growth | 110.471% | |
| Fiscal Year-end | 12 / 2026 | Employees | 122 | |
| View SEC Filings |
IVVD Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 7.962 |
| Price to Book Ratio | 2.884 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -3.764 |
| Enterprise Value to Sales | 3.765 |
| Total Debt to Enterprise Value | 0.012 |
IVVD Efficiency
| Revenue/Employee | 437,918.033 |
| Income Per Employee | -430,237.705 |
| Receivables Turnover | 3.661 |
| Total Asset Turnover | 0.263 |
IVVD Liquidity
| Current Ratio | 7.244 |
| Quick Ratio | 7.236 |
| Cash Ratio | 6.636 |
IVVD Profitability
| Gross Margin | 89.043 |
| Operating Margin | -103.994 |
| Pretax Margin | -98.246 |
| Net Margin | -98.246 |
| Return on Assets | -25.831 |
| Return on Equity | -33.965 |
| Return on Total Capital | -21.509 |
| Return on Invested Capital | -33.836 |
IVVD Capital Structure
| Total Debt to Total Equity | 1.033 |
| Total Debt to Total Capital | 1.022 |
| Total Debt to Total Assets | 0.901 |
| Long-Term Debt to Equity | 0.489 |
| Long-Term Debt to Total Capital | 0.484 |